Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT04613674 | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | completed | Phase 3 | 441 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 27, 2024 |
| clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | completed | Phase 3 | 5,351 | NSABP Foundation IncNETWORK | 2 | Mar 21, 2024 | clinicaltrials |
| NCT00295646 | Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | completed | Phase 3 | 1,803 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 2 | Mar 15, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT03337724 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer(IPATunity130) | completed | Phase 3 | 579 | Hoffmann-La RocheINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT01822314 | Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer(ETNA) | completed | Phase 3 | 632 | Fondazione MichelangeloOTHER | 6 | Mar 7, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT05338723 | Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients | completed | Phase 3 | 50 | Tanta UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT00630032 | Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer(TavIx) | completed | Phase 3 | 762 | UNICANCEROTHER | 3 | Feb 21, 2024 | clinicaltrials |
| NCT03265574 | PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?(PROACT) | completed | Phase 3 | 111 | South Tees Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT01864746 | A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery(PENELOPE-B) | completed | Phase 3 | 1,250 | GBG Forschungs GmbHOTHER | 11 | Dec 12, 2023 | clinicaltrials |
| NCT02422615 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-3) | completed | Phase 3 | 726 | Novartis PharmaceuticalsINDUSTRY | 30 | Nov 30, 2023 | clinicaltrials |
| NCT04239716 | Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection | completed | Phase 3 | 13 | Tanta UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT03262935 | SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer(TULIP) | completed | Phase 3 | 437 | Byondis B.V.INDUSTRY | 11 | Oct 19, 2023 | clinicaltrials |
| NCT02068092 | Olive Oil for High Risk Breast Cancer Prevention in Women | completed | Phase 2 / Phase 3 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03200704 | A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer(FILM-B) | completed | Phase 3 | 152 | Novadaq Technologies ULC, now a part of StrykerINDUSTRY | 2 | Sep 21, 2023 | clinicaltrials |
| NCT01101438 | A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer | completed | Phase 3 | 3,649 | Canadian Cancer Trials GroupNETWORK | 4 | Sep 13, 2023 | clinicaltrials |
| NCT00066573 | Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer | completed | Phase 3 | 7,576 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 25, 2023 | clinicaltrials |
| NCT00083174 | Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer(ExCel) | completed | Phase 3 | 4,560 | NCIC Clinical Trials GroupNETWORK | 4 | Aug 25, 2023 | clinicaltrials |
| NCT00754845 | Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy | completed | Phase 3 | 1,918 | Canadian Cancer Trials GroupNETWORK | 2 | Aug 25, 2023 | clinicaltrials |
| NCT03686215 | Investigation of Novel Surgical Imaging for Tumor Excision(INSITE) | completed | Phase 3 | 406 | Lumicell, Inc.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT04822597 | Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer | completed | Phase 3 | 167 | University of Wisconsin, MadisonOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT00556374 | Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | completed | Phase 3 | 3,420 | AmgenINDUSTRY | 2 | Jul 27, 2023 | clinicaltrials |
| NCT03252431 | Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | completed | Phase 3 | 393 | EVIVE BiotechnologyINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00309478 | Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | completed | Phase 3 | 1,099 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Jun 29, 2023 | clinicaltrials |
| NCT00003010 | Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy | completed | Phase 3 | 334 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00003519 | Combination Chemotherapy in Treating Women With Breast Cancer | completed | Phase 3 | 2,778 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00004125 | Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00026286 | Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00028990 | Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 3 | 722 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT05727098 | Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy. | completed | Phase 2 / Phase 3 | 75 | National Cancer Institute, EgyptOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00128310 | Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients | completed | Phase 3 | 252 | Spanish Breast Cancer Research GroupOTHER | 2 | May 31, 2023 | clinicaltrials |
| NCT05110170 | Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® | completed | Phase 3 | 188 | Luye Pharma Group Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT03084939 | Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 3 | 351 | Hoffmann-La RocheINDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT02915744 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine(ATTAIN) | completed | Phase 3 | 178 | Nektar TherapeuticsINDUSTRY | 10 | Apr 14, 2023 | clinicaltrials |
| NCT03564171 | Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer | completed | Phase 2 / Phase 3 | 63 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01875367 | Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer(ChangHER-SC) | completed | Phase 3 | 166 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT00121992 | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment | completed | Phase 3 | 1,060 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT00129935 | EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer | completed | Phase 3 | 1,384 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT00130533 | Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients | completed | Phase 3 | 876 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT00545077 | Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women | completed | Phase 3 | 380 | Spanish Breast Cancer Research GroupOTHER | 2 | Mar 31, 2023 | clinicaltrials |
| NCT03447132 | Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant(SAFIA) | completed | Phase 3 | 354 | International Cancer Research Group, United Arab EmiratesOTHER | 8 | Mar 10, 2023 | clinicaltrials |
| NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | completed | Phase 3 | 1,925 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 27, 2024source: clinicaltrials